Organon & Co. (NYSE:OGN) Shares Bought by HB Wealth Management LLC

HB Wealth Management LLC lifted its stake in shares of Organon & Co. (NYSE:OGN) by 64.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,114 shares of the company’s stock after acquiring an additional 7,081 shares during the period. HB Wealth Management LLC’s holdings in Organon & Co. were worth $270,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Retireful LLC purchased a new position in Organon & Co. in the fourth quarter valued at approximately $187,000. Quad Cities Investment Group LLC raised its stake in shares of Organon & Co. by 37.5% in the 4th quarter. Quad Cities Investment Group LLC now owns 15,211 shares of the company’s stock valued at $227,000 after acquiring an additional 4,146 shares during the period. 180 Wealth Advisors LLC lifted its holdings in shares of Organon & Co. by 40.1% during the 4th quarter. 180 Wealth Advisors LLC now owns 58,293 shares of the company’s stock valued at $870,000 after acquiring an additional 16,697 shares in the last quarter. Horizon Bancorp Inc. IN boosted its position in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after purchasing an additional 1,585 shares during the period. Finally, Wedmont Private Capital increased its holdings in Organon & Co. by 453.4% in the 4th quarter. Wedmont Private Capital now owns 100,539 shares of the company’s stock valued at $1,594,000 after purchasing an additional 82,372 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Trading Down 2.7 %

NYSE:OGN opened at $15.97 on Friday. The stock has a market cap of $4.11 billion, a price-to-earnings ratio of 3.17, a price-to-earnings-growth ratio of 0.87 and a beta of 0.76. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The business’s 50-day simple moving average is $15.36 and its 200 day simple moving average is $18.09.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.78 EPS. As a group, sell-side analysts predict that Organon & Co. will post 3.82 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were given a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 7.01%. The ex-dividend date of this dividend was Tuesday, November 12th. Organon & Co.’s payout ratio is currently 22.22%.

Wall Street Analysts Forecast Growth

Separately, TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.